Navin Fluorine International (532504) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 consolidated revenue grew 7% year-over-year to INR 523.68 crore, driven by robust HPP performance, but operating EBITDA declined 12% to INR 100.4 crore and PAT fell 17% to INR 51.2 crore due to margin pressures and higher depreciation.

• Specialty chemicals and CDMO segments faced headwinds from global agro inventory rationalization and deferred purchasing, while HPP saw strong growth.

• Multiple capacity expansion projects are progressing on schedule, including major CapEx in agro specialty, AHF, cGMP4, and R-32.

• Management remains optimistic about margin improvement and stronger performance in the second half of FY25.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, were approved by the Board and reviewed by statutory auditors.

Financial highlights

• Q1 FY25 consolidated revenue: INR 523.68 crore, up 7% year-over-year; standalone revenue: INR 376.28 crore, up 7% year-over-year.

• Operating EBITDA: INR 100 crore, down 12% year-over-year; margin at 19.2% vs 23.3% in Q1 FY24.

• Profit after tax: INR 51.2 crore, down 17% year-over-year; standalone PAT: INR 50.02 crore, down 21% year-over-year.

• Operating cash flow: INR 107 crore in Q1 FY25, supported by working capital improvements.

• No exceptional items impacted Q1 FY25; prior year included a gain from sale of surplus land.

Outlook and guidance

• Margin trajectory expected to improve gradually through FY25, with recovery in specialty chemicals and agro demand anticipated in H2 FY25.

• CDMO segment expected to surpass FY24 performance, with $100 million revenue aspiration by FY27.

• Peak revenue from new INR 540 crore CapEx targeted by FY27, with 24-25% EBITDA margin guidance.

• CapEx projects on track: INR 450 crore AHF plant by end FY25/early FY26, INR 84 crore R-32 expansion by Feb 2025, and INR 288 crore cGMP4 for CDMO by end CY2025.

• No forward-looking guidance or outlook was provided in the reviewed period.